3SBio (SEHK:1530) Stock Sees Margin Strength Clash With Profit Decline

Simply Wall St.

08/21

3SBio stock closed at HK$17.83 on Friday, roughly flat over the past month, even as the latest half year numbers landed with a heavy focus on profitability. The headline is simple. H1 2026 brought in ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2661295126"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2661295126\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2661295126?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-21 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661295126","market":"nz","top_or_hot":-1,"title":"3SBio (SEHK:1530) Stock Sees Margin Strength Clash With Profit Decline","media":"Simply Wall St.","content":"<div>\n<p>3SBio stock closed at HK$17.83 on Friday, roughly flat over the past month, even as the latest half year numbers landed with a heavy focus on profitability. The headline is simple. H1 2026 brought in ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-stock-sees-margin-strength-clash-with-profit\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3SBio (SEHK:1530) Stock Sees Margin Strength Clash With Profit Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3SBio (SEHK:1530) Stock Sees Margin Strength Clash With Profit Decline\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-08-21 21:20</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>3SBio stock closed at HK$17.83 on Friday, roughly flat over the past month, even as the latest half year numbers landed with a heavy focus on profitability. The headline is simple. H1 2026 brought in ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-stock-sees-margin-strength-clash-with-profit\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-stock-sees-margin-strength-clash-with-profit\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FEBU","symbol_name":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-stock-sees-margin-strength-clash-with-profit","article_id":"2661295126","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-sehk1530-stock-sees-margin-strength-clash-with-profit","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2661295126","pubTimestamp":1787318409,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"3SBio stock closed at HK$17.83 on Friday, roughly flat over the past month, even as the latest half year numbers landed with a heavy focus on profitability. The headline is simple. H1 2026 brought in C¥4,525.985m of revenue, yet the story that matters is margin strength and what that might mean for future earnings power.\nInvestors now face a time horizon test. Trailing earnings growth and a P/E around 4.6x paint one picture. Forecasts that point to declining revenue and earnings over the next...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","RGLO":"Global Equity Active ETF","VOTE":"TCW Transform 500 ETF","BK1583":"高瓴概念","VGFPF":"Vanguard Funds PLC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","GXDW":"Global X Dorsey Wright Thematic ETF","01530":"三生制药","BK1593":"医美概念股","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","BK1161":"生物科技"},"translate_title":"三生制药 (SEHK:1530) 股票利润率强劲与利润下降发生冲突","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DECU":0.79,"FEBU":0.79,"PMDE":0.79,"VOTE":0.79,"JOYT":0.79,"VGFPF":0.79,"RGLO":0.79,"GXDW":0.79,"01530":0.9},"content_text":"3SBio stock closed at HK$17.83 on Friday, roughly flat over the past month, even as the latest half year numbers landed with a heavy focus on profitability. The headline is simple. H1 2026 brought in C¥4,525.985m of revenue, yet the story that matters is margin strength and what that might mean for future earnings power. Investors now face a time horizon test. Trailing earnings growth and a P/E around 4.6x paint one picture. Forecasts that point to declining revenue and earnings over the next three years paint another. The rest of this report unpacks that tension. Love 3SBio’s current margin strength but concerned about forecasts pointing to falling revenue and earnings? Check out the 293 resilient stocks with low risk scores for stocks that pair resilient balance sheets with lower fundamental risk scores. AdvertisementH1 2026 Earnings Summary  Revenue, H1 2026 vs. H1 2025: C¥4,525.985m vs. C¥4,355.485m (up about 3.9%) Net Income (Excl. Extra Items), H1 2026 vs. H1 2025: C¥1,146.595m vs. C¥1,358.204m (down about 15.6%) Basic EPS, H1 2026 vs. H1 2025: C¥0.451816 vs. C¥0.566594 (down about 20.3%) Trailing Net Profit Margin, last 12 months vs. prior year: 46.3% vs. 26% (margin level materially higher year on year)  Prefer clear charts instead of another wall of earnings tables and footnotes? See 3SBio’s full financial picture, including a visual breakdown of its profitability and margins, in the company report for 3SBio. SEHK:1530 Trailing 12-Month Earnings & Revenue History as at Aug 2026 3SBio margins keep the constructive story alive For investors leaning positive on 3SBio, the latest figures still support a resilient operational story. Revenue in H1 2026 moved modestly ahead of H1 2025, which suggests the marketed portfolio is at least holding its ground. The standout is profitability. The trailing net profit margin of 46.3% versus 26% a year earlier points to much tighter cost control or a richer mix. Even with lower half year net income and EPS, that margin profile keeps the long term diversified biologics platform narrative intact. Profit slip and forecasts echo the cautious view The more cautious narrative around 3SBio also finds support in these results. Net income excluding extra items fell about 15.6% year on year and basic EPS dropped about 20.3%, which matches concerns about earnings pressure. Forecasts that indicate declining revenue and earnings over the next three years now sit alongside this near term profit contraction. Recent 90 day share performance, which is down about 7.3%, hints that the market is already pricing in some of these risks rather than treating the margin strength as a simple win. Compare 3SBio’s stronger trailing margins and lower recent profit with where the stock trades today, then see whether analysts think the risk reward still stacks up through the consensus price target analysis for 3SBio. Shape Your Next Investment Move If 3SBio’s strong margins and mixed earnings outlook have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and wait for a setup that fits your plan. When you decide to act, use the Portfolio Command Center to cut through market noise and focus on the updates that matter most to your holdings. For a longer term edge, tap into crowd insights and different angles on 3SBio and other stocks through the Community. By spotting potential catalysts and risks early, you may be able to stay ahead of market moves. Seeking Alternatives Beyond 3SBio Today Fresh stock ideas can move fast. Some sit under the radar for now, others build quiet momentum before a breakout. Do your homework before the crowd and get in early.  Spot cash generative businesses with room to move by scanning a curated 270 high quality undervalued stocks before potential momentum is fully caught by the broader market. Ride structural demand shifts by zeroing in on curated 39 power grid technology and infrastructure stocks while the story is still building and prices have not fully priced in the trend. Target stronger balance sheets and steadier compounding by working through a hand picked list of solid balance sheet and fundamentals stocks (426 results) before those stocks start flying on wider recognition.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if 3SBio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}